Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Aromatase inhibitors and inactivators in breast cancer.

× No keyword cloud information.

13 in total

Review 1. Aromatase inhibitors in the treatment and prevention of breast cancer.

Authors: P E Goss; K Strasser
Journal: J Clin Oncol Date: 2001-02-01 Impact factor: 44.544

2. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.

Authors: P E Lønning; E Bajetta; R Murray; M Tubiana-Hulin; P D Eisenberg; E Mickiewicz; L Celio; P Pitt; M Mita; N K Aaronson; C Fowst; A Arkhipov; E di Salle; A Polli; G Massimini
Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544

3. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

Authors: P Dombernowsky; I Smith; G Falkson; R Leonard; L Panasci; J Bellmunt; W Bezwoda; G Gardin; A Gudgeon; M Morgan; A Fornasiero; W Hoffmann; J Michel; T Hatschek; T Tjabbes; H A Chaudri; U Hornberger; P F Trunet
Journal: J Clin Oncol Date: 1998-02 Impact factor: 44.544

Review 4. Serum oestradiol and breast cancer risk.

Authors: T J Key
Journal: Endocr Relat Cancer Date: 1999-06 Impact factor: 5.678

5. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

Authors: M Kaufmann; E Bajetta; L Y Dirix; L E Fein; S E Jones; N Zilembo; J L Dugardyn; C Nasurdi; R G Mennel; J Cervek; C Fowst; A Polli; E di Salle; A Arkhipov; G Piscitelli; L L Miller; G Massimini
Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544

6. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.

Authors: A Buzdar; J Douma; N Davidson; R Elledge; M Morgan; R Smith; L Porter; J Nabholtz; X Xiang; C Brady
Journal: J Clin Oncol Date: 2001-07-15 Impact factor: 44.544

7. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.

Authors: J M Nabholtz; A Buzdar; M Pollak; W Harwin; G Burton; A Mangalik; M Steinberg; A Webster; M von Euler
Journal: J Clin Oncol Date: 2000-11-15 Impact factor: 44.544

8. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.

Authors: J Bonneterre; B Thürlimann; J F Robertson; M Krzakowski; L Mauriac; P Koralewski; I Vergote; A Webster; M Steinberg; M von Euler
Journal: J Clin Oncol Date: 2000-11-15 Impact factor: 44.544

Review 9. Antiaromatase agents: preclinical data and neoadjuvant therapy.

Authors: W R Miller; J M Dixon
Journal: Clin Breast Cancer Date: 2000-09 Impact factor: 3.225

10. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.

Authors: J Geisler; N King; G Anker; G Ornati; E Di Salle; P E Lønning; M Dowsett
Journal: Clin Cancer Res Date: 1998-09 Impact factor: 12.531

2 in total

Review 1. Breast cancer management: quality-of-life and cost considerations.

Authors: Davide Radice; Alberto Redaelli
Journal: Pharmacoeconomics Date: 2003 Impact factor: 4.981

2. A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation.

Authors: Marta Valle; Enrico Di Salle; Maria Gabriella Jannuzzo; Italo Poggesi; Maurizio Rocchetti; Riccardo Spinelli; Davide Verotta
Journal: Br J Clin Pharmacol Date: 2005-03 Impact factor: 4.335

2 in total